2022 Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type, and Key Players - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

This pipeline guide provides an overview of the Hepatic Encephalopathy pipeline landscape.

Companies Involved in Therapeutics Development

• Alfasigma SpA
• Axcella Health Inc
• Cosmo Pharmaceuticals NV
• Grifols SA
• Kaleido Biosciences Inc
• Neuropathix Inc
• Rebiotix Inc
• Takeda Pharmaceutical Co Ltd
• TenNor Therapeutics Ltd
• Umecrine Cognition AB
• Vedanta Biosciences Inc
• Versantis AG

Drug Profiles

• albumin (human)
• AXA-1665
• golexanolone
• KB-174
• KLS-13019
• KLS-13023
• RBX-2660
• RBX-7455
• rifamycin sodium CR
• rifaximin
• rifaximin SSD
• TAK-039
• TNP-2092
• VE-303
• VS-01
• VS-02

Report Highlights

This pipeline guide Hepatic Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatic Encephalopathy (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 8, 4 and 3 respectively.

Hepatic Encephalopathy (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hepatic Encephalopathy (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hepatic Encephalopathy (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy (Gastrointestinal)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hepatic Encephalopathy (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hepatic Encephalopathy (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered

Introduction

Report Coverage

Overview

Therapeutics Development

• Pipeline Overview
• Pipeline by Companies
• Products under Development by Companies

Therapeutics Assessment

• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Companies Involved in Therapeutics Development

Drug Profiles

Dormant Projects

Discontinued Products

Product Development Milestones

Featured News & Press Releases

• Jan 18, 2022: Neuropathix receives patent grant from India for its novel anti-inflammatory compounds
• Jan 11, 2022: Karolinska Development's portfolio company Umecrine Cognition presents preclinical data showing that golexanolone reduces neuroinflammation and counteracts motor symptoms
• Nov 02, 2021: Axcella Therapeutics announces upcoming presentation of AXA1665 at AASLD's The Liver Meeting 2021
• Jul 14, 2021: Karolinska Development's portfolio company Umecrine Cognition raises capital through a successful share issue
• Jun 30, 2021: Axcella announces initiation of EMMPOWER phase 2 clinical trial of AXA1665
• May 24, 2021: Positive clinical data about Axcella's AXA1665 candidate for overt hepatic encephalopathy highlighted in oral presentation at DDW 2021
• Apr 22, 2021: Axcella announces upcoming oral presentation at digestive disease week (ddw) 2021
• Apr 22, 2021: Karolinska Development's portfolio company Umecrine Cognition publishes clinical research results in a highly regarded journal
• Dec 29, 2020: Karolinska Development increases book value of Umecrine Cognition by SEK 234 million
• Oct 07, 2020: Kaleido Biosciences to present data from candidate KB174 at The Liver Meeting 2020
• Oct 06, 2020: Kannalife adds to its global IP estate receiving patent grant from Canada for its novel anti-inflammatory compounds
• Sep 02, 2020: Karolinska Development's portfolio company Umecrine Cognition presents results from clinical phase 2a study at AALSD International Liver meeting
• Aug 27, 2020: Kaleido Biosciences announces presentation of data for microbiome metabolic therapy KB174 for Hepatic Encephalopathy at The Digital International Liver Congress (EASL)
• Aug 25, 2020: Kannalife receives patent grants in additional European territories
• Aug 05, 2020: Axcella reports positive top-line data from AXA1665-002

For more information about this report visit https://www.researchandmarkets.com/r/aqcrye

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900